Thonningianin B

CAS No. 271579-12-5

Thonningianin B( —— )

Catalog No. M32670 CAS No. 271579-12-5

Thonningianin B is a natural product from Penthorum chinense Pursh.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 461 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock

Biological Information

  • Product Name
    Thonningianin B
  • Note
    Research use only, not for human use.
  • Brief Description
    Thonningianin B is a natural product from Penthorum chinense Pursh.
  • Description
    Thonningianin B is a natural product from Penthorum chinense Pursh.
  • In Vitro
    Cell Viability Assay Cell Line:BV-2 cells Concentration:0-100 μM Incubation Time:24 h Result:Inhibited viability with an IC50 of 46.74 μM.Cell Autophagy Assay Cell Line:BV-2 cells Concentration:10 μM Incubation Time:24 h Result:Significantly improved the ratio of LC3-II/LC3-I and the average number of GFP-LC3 puncta per cell.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    271579-12-5
  • Formula Weight
    722.6
  • Molecular Formula
    C35H30O17
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 66.67 mg/mL (92.26 mM)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Relatlimab

    Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.

  • Vanitiolide

    Vanitiolide is a choleretics.

  • MAGE-A3 195-203

    This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.